TC2 C776G polymorphism and oral cancer

Dear Editor
We read the publication on “TC2 C776G polymorphism studies in patients with oral cancer in the Polish population” with a great interest [1]. Malinowska et al. studied on polymorphism of transcobalamine 2 gene and concluded that “our population G/G homozygosity of C776G TC2 gene polymorphism increases the risk of oral cancer [1]” and “Regarding C/G genotype of the C776G TC2 gene, polymorphism also increases the risk of developing this cancer [1].” The results in this report are concordant with the previous report on this polymorphism and and head and neck squamous cell carcinoma risk [2]. A possible explanation for the observation might be due to the molecular change due to the G to C mutations. If we considered the molecular weight change based on molecular calculation at the mutation site, G776C, the change G to C is equal to +36.03 g/Mol (75.07 to 111.1). The increased molecular weight due to genetic change can imply a requirement of more molecules for completeness of final expression. This means an increased risk for carcinogenesis. It is the same biological process as described in in other malignancies [3, 4].
The authors declare no conflict of interest.

References

Malinowska K, Morawiec-Sztandera A, Majsterek I, Kaczmarczyk D. TC2 C776G polymorphism studies in patients with oral cancer in the Polish population. Pol J Pathol 2016; 67: 277-282.
da Silva LM, Galbiatti AL, Ruiz MT, et al. MTHFD1 G1958A, BHMT G742A, TC2 C776G and TC2 A67G polymorphisms and head and neck squamous cell carcinoma risk. Mol Biol Rep 2012; 39: 887-893.
Joob B, Wiwanitkit V. Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms and B-Cell Non-Hodgkin Lymphoma. Turk J Haematol 2018; 35: 301-302.
Sookaromdee P, Wiwanitkit V. Wilms Tumor-1 (WT1) rs16754 Polymorphism. Turk J Haematol. 2019; 36: 69-69.